

The Peptide Therapeutics Forum 2021

The event provides an innovative platform to exchange on the various aspects of drug development with a focus on peptides, including examples for successful development candidates. The forum disseminates information on latest news in the broad field and enables networking of interested parties from academia and industries.

The event will take place on-site for those who are able to join us in Basel or online for those who are not able to travel due to COVID-19 restrictions.

Fees and Registration

Non-members of the Swiss Chemical Society

- Online participation CHF 100
- On-site participation CHF 200

Swiss Chemical Society Members

- Online participation free of charge
- On-site participation CHF 100

Please register on ptf21.scg.ch

Deadline for on-site registration is **July 30, 2021**

Deadline for invoice payment is **July 30, 2021**

Deadline for short video poster abstracts is **July 9, 2021**

Venue

Universitätsspital Basel
Zentrum für Lehre und Forschung
Hebelstrasse 20, Basel

Online access to the conference (Zoom) will be provided on the website. Registration is mandatory.

Sponsors and Exhibitors of the 2020 Edition




ptf21.scg.ch

Division of Medicinal Chemistry
& Chemical Biology

Peptide Therapeutics Forum 2021

August 19-20, 2021

University Hospital, Basel



Swiss Chemical Society (SCS)
Haus der Akademien
Laupenstrasse 7
3008 Bern
info@scg.ch



SCS
Swiss Chemical
Society
**Division of
Medicinal Chemistry &
Chemical Biology**

Program, Thursday 19 August 2021

- 09.30 Welcome Address by the organizers
Chairs: **Prof. Melpomeni Fani**, University of Basel, Switzerland), **Prof. Roderich Süßmuth**, Technical University of Berlin, Germany & **Dr. Thomas Vorherr**, Basel, Switzerland
-
- 09.45 Special Guest Address by the graduate school “**Bioactive Peptides**”, a joint research initiative by the Berlin & Potsdam Universities
-
- 10.00 **Nina Hartrampf**, University of Zurich, Switzerland
«*Flow-based methods for chemical peptide and protein synthesis*»
- 10.30 **Steven Trim**, Venomtech, US
«*Discovery of stable, selective venom peptides for cancer research*»
-
- 11.00 Coffee Break
-
- 11.30 **Helena Safavi** University of Copenhagen, Denmark
«*Venom-inspired design of novel drug leads for diabetes*»
- 12.00 **Elisabeth von Guggenberg**, University Hospital Innsbruck, Austria
«*Peptide-based targeting strategies for diagnosis and therapy of medullary thyroid cancer*»
-
- 12.30 Lunch Break, Exhibition and Networking
-
- 14.00 **Plenary Lecture: Bart Cornelissen**, University of Oxford, UK
«*Radiolabelled peptides and conjugates for imaging and therapy of cancer*»
-
- 15.00 Coffee Break
-
- 15.30 **Gerardo Guillen**, Center for Genetic Engineering and Biotechnology, Cuba
«*The anti-inflammatory peptide CIGB-258 (Jusvinza) to treat COVID-19*»
- 16.00 **John Vrettos**, Enteris Biopharma, US
«*Strategies for oral delivery of peptides*»
- 16.30 **Manuel Sanchez**, Novartis, US
«*Patient-centric design for systemic peptide delivery: Trends in routes of administration and advancement in drug delivery technologies*»
-
- 17.00 End of Day 1
-

Program, Friday 20 August 2021

- 10.00 **Evi Kostenis**, University of Bonn, Germany
«*FR2900359: nature's weapon and treasure trove for basic and translational research*»
- 10.30 **Kristian Strømgaard**, Avilex Pharma / University of Copenhagen, Denmark
«*Targeting receptor complexes with therapeutic peptides*»
-
- 11.00 Coffee Break
-
- 11.30 **Norbert Sewald**, Bielefeld University, Germany
«*Cryptophycins and conjugates*»
- 12.00 **Deborah O'Neil**, Novobiotics, UK
«*Antimicrobial peptides for bacterial and fungal disease.*»
-
- 12.30 Lunch Break, Exhibition and Networking
-
- 14.00 **Daniel Obrecht**, Polyphor, Switzerland
«*Balixafortide: a potent macrocyclic peptide CXCR4 inhibitor for oncology therapies*»
- 14.30 **Jan Münch**, University of Ulm, Germany
«*Peptide Inhibitors of SARS-CoV-2 entry*»
-
- 15.00 Coffee Break
-
- 15.30 **Sridhar Nimmagadda**, John Hopkins University School of Medicine, US
«*Peptide-based PET to quantify the pharmacologic activity of PD(L)-1 therapeutics in the tumor bed*»
- 16.00 **Jesse Dong**, Biontech, US
«*Development of peptide-based personal cancer vaccine NEO-PV-01*»
- 16.30 **Dehua Pei**, Ohio State University, US
«*Intracellular biologics as next-generation therapeutics*»
-
- 17.00 End of the Peptide Therapeutics Symposium 2021
-

Chairs

Prof. Melpomeni Fani, University of Basel, Switzerland
Prof. Roderich Süßmuth, Technical University of Berlin, GER
Dr. Thomas Vorherr, Basel, Switzerland

Organizing Partner

